Agenda - Day 1

There are no agenda items with this track

7:30 am

7:30 am

Registration and Breakfast

8:15 am

8:15 am

Opening Remarks from the Chairs

8:30 am

8:30 am

Opening Keynote Address

Evaluate your Company’s Transition Plans to Improve Market Access Under the New PMPRB Rules

With the new pricing regulations now being implemented, it is a good opportunity to make an initial assessment on how industry is managing under the new regulatory reality.  Position your company to succeed during this transition period.  Gain valuable insight to help you get your product launches off to a good start by;

  • Navigating the new reporting requirements and how they apply to your products
  • Understanding how cost-effectiveness will be calculated and assessed
  • Gaining insight into how products targeted to smaller patient populations will be handled

Successfully manage the impact of pricing reform on your company’s bottom line

9:00 am

9:00 am

Panel Discussion

Strategies for Managing the Transition Under the New Pricing Regulations

The federal government has made it clear that pricing reform is fundamental to the adoption of a national pharmacare program.  Now that the new pricing regulations are being implemented, you need a forward strategy to succeed in this new uncertain environment.  Hear how your peers are tackling this transition and join in a discussion to address issues such as;

  • Dealing with multiple indications for a new drug
  • The criteria for determining which category applies to your product
  • Pricing transparency requirements and the Interim Maximum List Price that will be applied to your product

Be prepared for the future with new market access strategies to adapt to the new PMPRB guidelines

9:45 am

9:45 am

Panel Discussion – Streamlining the path to Market:

Regulatory Modernization – Is Canada a Land of Regulatory Obstacles or Opportunities?

The federal government has faced challenges in updating regulations to keep up with the modern changes to drug discovery and with market access. The result could be viewed as onerous regulatory burden or as regulatory clarity paving the way for future opportunities. Take back to your team actionable insights about:

  • The benefits expected from the current federal regulatory modernization project
  • Whether perceived regulatory burdens can be alleviated or reduced
  • How greater clarity in updated regulations can translate into opportunities for market access

Learn how to reduce regulatory burden and leverage regulatory modernization into increased opportunities

10:30 am

10:30 am

Networking Break

11:00 am

11:00 am

Keynote Address:

Evaluate the Impact of CADTH’s New Review Requirements and Advisory Committee

Earlier this year, CADTH introduced new submission review requirements and a merger of the Drug Policy and pCODR Advisory Committees. Understand the impact of these changes and adapt your submissions to be reviewed expediently. Source intelligence to:

  • Better understand the information requirements for both CDR and pCODR under this new advisory structure
  • Adopt best practices to better manage your product submissions under the revised process
  • Avoid pitfalls in your submission process with insight on what are the common mistakes made by others

Position your product to successfully navigate new HTA review requirements

11:30 am

11:30 am

Panel Discussion - Biosimilars

Gain Insights into the Impact of the Increasing Use of Biosimilars for Patients and the Marketplace

Many consider that increasing the use of biosimilars is key to putting healthcare budgets on a more financially sustainable path.  Understand the implications and opportunities for your business of recent policy decisions to foster a greater market share for biosimilars.  Develop an action plan to:

  • Prepare and support patients in the event they need to switch to a biosimilar
  • Analyse the impact on your biosimilar strategy of international collaboration to increase biosimilar market share
  • Adapt your Canadian market access strategies with medical and public policy guidance

Inform your strategy for biosimilars with key public policy insights.

12:15 pm

12:15 pm

Networking Lunch

1:00 pm

1:00 pm

Keynote Luncheon Address:

Position Your Organization to Benefit from Greater International Regulatory Alignment and Collaboration

Getting needed safe new therapies to market and to patients as quickly as possible is everyone’s goal.  In order to expedite the submission process, efforts are being made to improve international collaboration to reduce duplication between countries.  Gain valuable insights into new developments that could improve market access for your products.  Take away ideas to enhance your submission strategies by:

  • Understanding the latest news about how Canada is collaborating internationally to streamline its submission process.
  • Gaining insights into the extent to which regulatory alignment will occur and what differences will remain between countries
  • Learning what other countries are involved and how expertise is being shared

Reduce regulatory burden and gain efficiencies for your multi-national drug submissions

1:15 pm

1:15 pm

Panel Discussion

Adapt Your Strategy to an Uncertain Marketplace and Succeed in Securing PLA’s

With new pricing regulations and HTA submission requirements now in effect, securing a workable PLA may seem like a daunting task. Analyze and evaluate the regulatory landscape to forge a path forward. Source intelligence for a plan of action by:

  • Gaining insight into what impact the new PMPRB regulations may be having on procurement decisions
  • Understanding what new developments are underway that will impact your approach to members of the pCPA
  • Learning how to be proactive in managing the impact of major changes on the horizon for Canada’s procurement processes

Position your company to succeed in a transitional policy and regulatory environment

1:45 pm

1:45 pm

Panel Discussion:

Elevate Your Submission Strategy for PLA’s with Private Payers

Continued tightening of access to private payor formularies combined with a move to outsource benefit plan and administration to third parties for some payers, means more barriers to access this market than before. Hone your private payor access strategy by understanding new market developments and payor priorities. Create an action plan to:

  • Leverage elements of successful public PLA submissions and adapt them for the private payer market
  • Analyze the influence of public payer decisions on private payors to increase your preparedness
  • What pharma companies can do to optimize the ROI of their submissions to private payers

Gain insight into what private payers need and succeed with a tailored approach to securing a PLA

2:15 pm

2:15 pm

Industry Expert:

Case Study – Gathering Real-world Evidence to Support Your Review Submission

Governments, players and healthcare’s other stakeholders are increasingly required to incorporate quality data to support their submissions for reimbursement.  Explore new approaches to using Real World Evidence to improve the value proposition your medicines bring to the decision process and to patients.  Take away strategies to:

  • Enhance the efficacy of your medications on individual patient outcomes
  • Evaluate the impact on the health of the overall patient population for your medication
  • Partner with your stakeholders to access data

Prove and improve the value, efficacy and impact of your medications with RWE

2:45 pm

2:45 pm

Networking Break

3:15 pm

3:15 pm

Industry Expert:

Meet the Expectations of Health Professionals and Patients with a Reliable Drug Distribution System

Having a reliable distribution system to deliver your products to patients and health professionals is critical, and with today’s more specialized therapies, requirements for their transport have become more rigorous.  Analyse your distribution requirements to develop the best strategy for your products.  Take away ideas to help you:

  • Remove an incentive for patients to switch medications by identifying potential constrictions in your distribution network and keep your products moving
  • Identify which products require more stringent standards to meet Health Canada regulations
  • Ensure that your products meet quality assurance standards right up to delivery

Avoid interruptions in your product delivery system that could cause patients to switch medications.

3:45 pm

3:45 pm

Panel Discussion:

Patient perspective – Instil the Patients’ Voice into Your Market Access Strategy to Enhance Your Product’s Success

Involving patient groups has become a cornerstone to the success of new product launches. Advance the validity of your R&D results and your market access strategy by incorporating the patient voice from the earliest possible stage of development. Create a blueprint to:

  • Initiate greater collaboration with patient groups earlier on
  • Understand the benefits of involving patients in the trial design stage
  • Gain early insight into how patients react to your product that can enhance your success throughout your development cycle and beyond to patient support

Instil the patients’ voice into your R&D to advance your market access strategy

4:30 pm

4:30 pm

Conference Adjourns, Event Reception Begins

Get the latest news

*Privacy Policy